We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Feature

Drug Patent Challenges At PTAB By The Numbers

Law360 (June 21, 2018, 9:04 PM EDT) -- The Patent Trial and Appeal Board has not been the graveyard for drug patents that some might expect as it's been invalidating these patents at virtually the same rate as district courts, according to a new study that challenges some of the conventional wisdom about the PTAB.

The analysis, conducted by attorneys at Ropes & Gray LLP, looked at all America Invents Act reviews involving patents for approved drug products through May 1. It also considered district court decisions in lawsuits over generic drugs during roughly...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.